Evaluation of adverse events focusing on infection associated with infliximab originator and biosimilar using a spontaneous reporting system database

Evaluation of adverse events focusing on infection associated with infliximab originator and biosimilar using a spontaneous reporting system database

Abstract Background Infliximab (IFX) has changed the management of many life-threatening immune-mediated diseases. The high cost of IFX and its patent expiry have led to pharmaceutical companies developing a biosimilar; however, its safety profile remains unknown in the real world. The purpose of th...

Full description

Bibliographic Details
Main Authors: Iku Niinomi, Keiko Hosohata, Yasuhiro Mori, Yuki Yamaguchi, Tomohito Wakabayashi, Mayako Uchida, Kazunori Iwanaga
Format: Article
Language:English
Published: BMC 2019-10-01
Series:Journal of Pharmaceutical Health Care and Sciences
Subjects:
Biosimilar
Infliximab
Adverse drug events
Spontaneous reporting system
Reporting odds ratio (ROR)
Japanese Adverse Drug Event Report (JADER) database
Online Access:http://link.springer.com/article/10.1186/s40780-019-0149-z

Internet

http://link.springer.com/article/10.1186/s40780-019-0149-z

Similar Items